Kaiser Foundation Hospitals and Medpace took part in a round that will support phase 3 trials for the startup's lead cardiometabolic disease drug candidate.

Netherlands-based cardiometabolic disease drug developer NewAmsterdam Pharma closed a $196m series A round yesterday that included healthcare provider Kaiser Foundation Hospitals and clinical research organisation Medpace.

Morningside Ventures and Ascendant BioCapital co-led the round, which also featured Forbion, BVF Partners, Population Health Partners, LSP Dementia Fund, Janus Henderson Investors, GL Capital, JVC Investment Partners, Presight Capital and angel investor Peter Thiel.

NewAmsterdam is working on treatments for cardiometabolic diseases, a disease class that include cardiovascular disease, stroke, diabetes and non-alcoholic…

Robert Lavine

Robert Lavine is special features editor for Global Venturing.